Uric Acid

Uric Acid

SCHEMBL921153

O=c1[nH]c(=O)c2[nH]c(=O)[nH]c2[nH]1.[KH]

nearest known ligand 0.94

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GDA Q9Y2T3 2/20 0.94
ALDH1A1 P00352 4/20 0.46
CYP1A2 P05177 2/20 0.46
CYP2C9 P11712 2/20 0.46
HPGD P15428 2/20 0.46
CYP2C19 P33261 2/20 0.46
HSD17B10 Q99714 2/20 0.46
ALOX15 P16050 1/20 0.46
MAPT P10636 3/20 0.46
KDM4E B2RXH2 2/20 0.46
GAA P10253 1/20 0.46
PKM P14618 1/20 0.46
BRPF1 P55201 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
TYMP P19971 5/20 0.39
GSK3B P49841 1/20 0.39
BACE1 P56817 1/20 0.39
IDH1 O75874 1/20 0.39
CSNK2A2 P19784 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Uric Acid SCHEMBL447964 1.00 GDA (0.94) GDAALDH1A1CYP1A2CYP2C9HPGD
Uric Acid SCHEMBL30062557 0.97 GDA (1.00) GDAALDH1A1CYP1A2CYP2C9HPGD
Uric Acid SCHEMBL3417988 0.97 GDA (1.00) GDAALDH1A1CYP1A2CYP2C9HPGD
Uric Acid SCHEMBL7933 0.97 GDA (1.00) GDAALDH1A1CYP1A2CYP2C9HPGD
Uric Acid SCHEMBL22069923 0.97 GDA (1.00) GDAALDH1A1CYP1A2CYP2C9HPGD
Uric Acid SCHEMBL11473111 0.95 GDA (0.84) GDAALDH1A1CYP1A2CYP2C9HPGD
Uric Acid SCHEMBL10631703 0.94 GDA (0.94) GDAALDH1A1CYP1A2CYP2C9HPGD
Uric Acid SCHEMBL2434620 0.94 GDA (0.94) GDAALDH1A1CYP1A2CYP2C9HPGD
Uric Acid SCHEMBL16213309 0.94 GDA (0.94) GDAALDH1A1CYP1A2CYP2C9HPGD
Uric Acid SCHEMBL229866 0.94 GDA (0.94) GDAALDH1A1CYP1A2CYP2C9HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014404-A1 LONG-TERM FIRE RETARDANT WITH CORROSION INHIBITORS AND METHODS FOR MAKING AND USING SAME PERIMETER SOLUTIONS, LP (US) 2026-01-15 US claimed
WO-2025264733-A1 LONG-TERM FIRE RETARDANT WITH CORROSION INHIBITORS AND METHODS FOR MAKING AND USING SAME PERIMETER SOLUTIONS, LP (US) 2025-12-26 WO claimed
WO-2023191907-A1 LONG-TERM FIRE RETARDANT WITH CORROSION INHIBITORS AND METHODS FOR MAKING AND USING SAME FRS GROUP, LLC (US) 2023-10-05 WO claimed
CN-108662052-A A kind of luffa preliminary working method 陕西理工大学 2018-10-16 CN claimed
US-6916426-B2 Method of waste treatment ATD WASTE SYSTEMS INC. (CA) 2005-07-12 US claimed
CN-1258448-A Hand disinfectant for preoperation use and personal hygiene and its preparation TIANJIN AIHUA FRESHENER CO LTD (CN) 2000-07-05 CN claimed
JP-61183204-A None JP disclosed
US-20260014404-A1 LONG-TERM FIRE RETARDANT WITH CORROSION INHIBITORS AND METHODS FOR MAKING AND USING SAME PERIMETER SOLUTIONS, LP (US) 2026-01-15 US disclosed
WO-2025264733-A1 LONG-TERM FIRE RETARDANT WITH CORROSION INHIBITORS AND METHODS FOR MAKING AND USING SAME PERIMETER SOLUTIONS, LP (US) 2025-12-26 WO disclosed
US-20250186600-A1 EXCIPIENT COMPOUNDS FOR PROTEIN FORMULATIONS COMERA LIFE SCIENCES, INC. 2025-06-12 US disclosed
US-20250121235-A1 LONG-TERM FIRE RETARDANT WITH CORROSION INHIBITORS AND METHODS FOR MAKING AND USING SAME FRS GROUP, LLC (US) 2025-04-17 US disclosed
US-12109446-B2 Long-term fire retardant with corrosion inhibitors and methods for making and using same FRS GROUP, LLC (US) 2024-10-08 US disclosed
US-20240269501-A1 LONG-TERM FIRE RETARDANT WITH CORROSION INHIBITORS AND METHODS FOR MAKING AND USING SAME FRS GROUP, LLC (US) 2024-08-15 US disclosed
US-4966776-A ADMINISTERING A DAILY DOSAGE OF COMPOSITION COMPRISING POTASSIUM CITRATE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 1990-10-30 US disclosed
US-4961925-A HAIR DYE COMPRISING DIELECTRON REDUCING OXIDASE UTILIZING OXYGEN AS ACCEPTOR KYOWA HAKKO KOGYO CO., LTD. (JP) 1990-10-09 US disclosed
US-4888182-A ADMINISTERING POTASSIUM CITRATE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 1989-12-19 US disclosed
WO-1989001471-A1 METHOD FOR DETECTING APPENDICITIS BAR OR DAVID (US) 1989-02-23 WO disclosed
JP-S61183204-A COSMETIC RIKEN VITAMIN CO LTD 1986-08-15 JP disclosed
US-4196290-A KILLING MICROORGANISMS THE GATES RUBBER COMPANY (US) 1980-04-01 US disclosed
US-4045582-A FEED SUPPLEMENT THE GATES RUBBER COMPANY (US) 1977-08-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014404-A1 LONG-TERM FIRE RETARDANT WITH CORROSION INHIBITORS AND METHODS FOR MAKING AND USING SAME SLC6A12, SLC11A2, KCNN1 GDA 4839/4885ALDH1A1 4616/4885CYP1A2 2552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.